Immune dominant HLA-A3 super-type restrictive CTL epitope of hepatitis B virus core antigen and identification method and application thereof

A technology of HLA-A3 and core antigen, which is applied in antiviral agents, biochemical equipment and methods, and microbial determination/inspection, etc., to reduce research costs, reduce workload, and speed up research progress

Inactive Publication Date: 2011-02-23
ARMY MEDICAL UNIV
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the research on HLA-A3 supertype-restricted CTL epitopes derived from HBV is limited to polymerase, and the HLA-A3 supertype-restricted CTL epitopes reported in the literature have only been initially confirmed from the aspect of affinity, but not from the aspect of stimulating CTL responses. confirmed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Immune dominant HLA-A3 super-type restrictive CTL epitope of hepatitis B virus core antigen and identification method and application thereof
  • Immune dominant HLA-A3 super-type restrictive CTL epitope of hepatitis B virus core antigen and identification method and application thereof
  • Immune dominant HLA-A3 super-type restrictive CTL epitope of hepatitis B virus core antigen and identification method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0021] Hereinafter, preferred embodiments of the present invention will be described in detail with reference to the accompanying drawings.

[0022] 1. Prediction of immunodominant HLA-A3 supertype-restricted CTL epitopes of HBcAg

[0023] The amino acid sequence (P03138) of the HBcAg registered in GenBank utilizes five online epitope prediction websites: SYFEPITHI (http: / / www.syfpeithi.de / Scripts / MHCServer.dll / EpitopePrediction.htm), BIMAS (http: / / www. - bimas.cit.nih.gov / molbio / hla_bind / ), SVMHC (http: / / www-bs.informatik.uni-tuebingen.de / Services / SVMHC), IEDB (http: / / tools.immunepitope.org / analyze / html / mhc_binding.html) and EpiJen (http: / / www.darrenflower.info / EpiJen / ) for immunodominant HLA-A3 supertype-restricted CTL epitope prediction: set MHC molecular restriction as HLA- A*0301, HLA-A*1101, HLA-A*3101, HLA-A*3301 and HLA-A*6801, the candidate epitope length is 9 peptides and 10 peptides; the cutoff value (cutoff) of different prediction algorithms is different: SYFPE...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an antigen epitope, in particular to an immune dominant HLA-A3 (human leukocyte antigen A3) super-type restrictive CTL (cytotoxic T lymphocyte) epitope of a hepatitis B virus core antigen (HBcAg) and an identification method for the super-type CTL epitope. The super-type CTL epitope consists of the following amino acid sequence: Leu-Leu-Asp-Thr-Ala-Ser-Ala-Leu-Tyr-Arg. The method is also suitable for identification of other antigen super-type CTL epitopes, and can provide a useful tool for design and research of therapeutic polypeptide vaccines. The invention also relates to application of the super-type CTL epitope in preparing hepatitis B therapeutic polypeptide vaccines, and provides a new strategy and a new method for efficient research of the hepatitis B therapeutic polypeptide vaccines. The method is expected to break through hepatitis B immune tolerance, reconstruct the immune function of cells and efficiently inhibit and clear hepatitis B viruses.

Description

technical field [0001] The present invention relates to an antigenic epitope, in particular to the immunodominant HLA-A3 supertype (supertype) restricted CTL (cytotoxic T lymphocyte) epitope of hepatitis B virus core antigen (HBcAg), and also relates to the supertype CTL epitope Bit identification methods and applications. Background technique [0002] Hepatitis B (Hepatitis B) is an infectious disease that seriously endangers human health caused by infection with hepatitis B virus B (Hepatitis B virus, HBV). At present, there are about 400 million HBV carriers in the world, mainly in developing countries. Globally, China is a high prevalence area, HBV carriers account for about 10% of the total population (120 million), and chronic hepatitis patients are about 30 million. Hepatitis B is mostly transmitted during the perinatal period, with onset in adolescence and exacerbation in young and middle-aged people, so most of the people at risk are young and middle-aged. Most p...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68G01N33/53A61K39/29A61P1/16G01N15/10C07K7/06A61P31/20
Inventor 王莉王文博王书峰吴玉章
Owner ARMY MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap